SCHEMBL17135240

SCHEMBL17135240

Cc1c(Cl)ncc(C(=O)O)c1Nc1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.60
▸ MAPT P10636 1/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ AKR1C3 P42330 2/20 0.49
▸ AKR1C2 P52895 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CSNK2A2 P19784 2/20 0.48
▸ CSNK2B P67870 2/20 0.48
▸ CSNK2A1 P68400 2/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ PDE4B Q07343 1/20 0.47
▸ XDH P47989 1/20 0.46
▸ SLC22A12 Q96S37 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ HDAC3 O15379 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17134793 0.87 EGFR (0.60) EGFRMAPTMEN1KMT2AAKR1C3
SCHEMBL17134561 0.80 EGFR (0.49) EGFRMAPTMEN1KMT2AAKR1C3
SCHEMBL17134843 0.77 EGFR (0.54) EGFRMAPTMEN1KMT2AAKR1C3
SCHEMBL17134582 0.76 MEN1 (0.48) MAPTMEN1KMT2AAKR1C3AKR1C2
SCHEMBL17134974 0.76 EGFR (0.54) EGFRMAPTMEN1KMT2AAKR1C3
SCHEMBL17135090 0.76 CNR2 (0.44) EGFRMAPTSMN1; SMN2CSF1RCNR2
SCHEMBL25394855 0.76 EGFR (0.74) EGFRMAPTMEN1KMT2ALMNA
SCHEMBL17134871 0.74 CNR2 (0.45) MAPTSMN1; SMN2CNR2
SCHEMBL12501075 0.73 CYP1A2 (0.68) EGFRMAPTMEN1KMT2ALMNA
SCHEMBL13842076 0.72 KMT2A (0.43) EGFRMAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
CN-104995173-A Nitrogen-containing heterocyclic compound KYOWA HAKKO KIRIN CO LTD 2015-10-21 — — CN disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR EGFR 2581/4885MAPT 4384/4885MEN1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback